Ts'ao C H
Artery. 1979 Mar;5(3):246-61.
The vessel wall contains powerful inhibitors of thrombogenesis. One substance, a proteoglycan, is a strong anticoagulant but has only a limited effect on platelet aggregation. It prolongs the thrombin clotting time and partial thromboplastin time, but only blocks platelet aggregation induced by thrombin. Another vessel wall constituent, a prostaglandin derivative (prostacyclin), is a potent inhibitor of platelet aggregation. It antagonizes platelet aggregation induced by a variety of agents including adenosine diphosphate, collagen, arachidonic acid and thrombin; however, its only effect on coagulation is through the inhibition of platelet factor-3 release. Proteoglycans and prostacyclin comlement each other's antithrombotic activities, and together serve to limit the hemostatic response of blood to vessel wall injury. Vessels devoid of the intima continue to produce prostacyclin. Prostacyclin produced by these vessels is probably more important than that produced by vessels with the intima in the prevention of thrombus deposition.
血管壁含有强大的血栓形成抑制剂。一种物质，即蛋白聚糖，是一种强效抗凝剂，但对血小板聚集的作用有限。它可延长凝血酶凝血时间和部分凝血活酶时间，但仅能阻断由凝血酶诱导的血小板聚集。血管壁的另一种成分，即前列腺素衍生物（前列环素），是一种有效的血小板聚集抑制剂。它可拮抗由多种物质诱导的血小板聚集，包括二磷酸腺苷、胶原、花生四烯酸和凝血酶；然而，它对凝血的唯一作用是通过抑制血小板因子3的释放。蛋白聚糖和前列环素相互补充彼此的抗血栓活性，并共同限制血液对血管壁损伤的止血反应。没有内膜的血管继续产生前列环素。这些血管产生的前列环素在预防血栓沉积方面可能比有内膜的血管产生的前列环素更重要。
